Impact of immune-related toxicity on survival and treatment response in non-small cell lung cancer patients

Alejandro Valcuende-Rosique; Corina Escoín-Pérez; Agustín Sánchez-Alcaraz; Virginia Merino

doi:10.1186/s12890-026-04185-3

February 20, 2026BMC Pulmonary MedicineOpen Access

Impact of immune-related toxicity on survival and treatment response in non-small cell lung cancer patients

View Full Paper

Ask AI

Bookmark

Share

Key Points

To explore the association between immune-related adverse events and patient outcomes in non-small cell lung cancer.
Analyzed data from NSCLC patients undergoing immune checkpoint inhibitor therapy.
Evaluated the presence of immune-related adverse events (irAEs).
Assessed treatment responses and overall survival rates.
Patients with irAEs showed improved survival rates compared to those without.
Enhanced treatment responses were noted in those experiencing irAEs.
Potential for irAEs to be used as predictive biomarkers for personalized treatment.

Implication

This research demonstrates enhanced survival and treatment response in NSCLC, suggesting irAEs may guide personalized therapies.

Abstract

The presence of irAEs is associated with enhanced survival and treatment response in NSCLC patients receiving ICIs. These findings underscore the potential of irAEs as predictive biomarkers, supporting personalized treatment strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Valcuende-Rosique et al. (2026) studied this question.

synapsesocial.com/papers/699a9cc6482488d673cd2734 https://doi.org/10.1186/s12890-026-04185-3

View Full Paper

Ask AI

Bookmark

Share

Impact of immune-related toxicity on survival and treatment response in non-small cell lung cancer patients

Key Points

Implication

Abstract

Discussion

Cite This Study

Impact of immune-related toxicity on survival and treatment response in non-small cell lung cancer patients

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading